Michael R. Michaelides

1.1k total citations
24 papers, 633 citations indexed

About

Michael R. Michaelides is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Michael R. Michaelides has authored 24 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 8 papers in Organic Chemistry. Recurrent topics in Michael R. Michaelides's work include HER2/EGFR in Cancer Research (8 papers), Microtubule and mitosis dynamics (5 papers) and Cancer Treatment and Pharmacology (4 papers). Michael R. Michaelides is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Microtubule and mitosis dynamics (5 papers) and Cancer Treatment and Pharmacology (4 papers). Michael R. Michaelides collaborates with scholars based in United States, United Kingdom and Japan. Michael R. Michaelides's co-authors include Michael L. Curtin, Steven K. Davidsen, Keith B. Glaser, Patrick A. Marcotte, Lori J. Pease, Kent D. Stewart, Wesley K. M. Chong, William Roush, Daniel H. Albert and Jennifer J. Bouska and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Michael R. Michaelides

23 papers receiving 596 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael R. Michaelides United States 16 338 261 155 70 44 24 633
Stuart B. Rosenblum United States 13 326 1.0× 173 0.7× 204 1.3× 64 0.9× 28 0.6× 23 725
Peter Chua Canada 11 323 1.0× 443 1.7× 111 0.7× 49 0.7× 28 0.6× 14 766
James M. Hamby United States 17 349 1.0× 542 2.1× 121 0.8× 80 1.1× 50 1.1× 32 828
Kristi Leonard United States 15 338 1.0× 253 1.0× 183 1.2× 31 0.4× 41 0.9× 24 699
H. Robin Heyman United States 14 275 0.8× 293 1.1× 136 0.9× 80 1.1× 23 0.5× 20 575
Arthur G. Taveras United States 16 283 0.8× 322 1.2× 310 2.0× 118 1.7× 68 1.5× 39 758
André Richters Germany 17 212 0.6× 480 1.8× 144 0.9× 111 1.6× 65 1.5× 24 776
Matthew Labenski United States 12 200 0.6× 405 1.6× 166 1.1× 37 0.5× 30 0.7× 20 701
Sung Yun Cho South Korea 15 277 0.8× 356 1.4× 115 0.7× 32 0.5× 29 0.7× 43 673
Robert A. Mantei United States 15 258 0.8× 308 1.2× 111 0.7× 95 1.4× 62 1.4× 24 621

Countries citing papers authored by Michael R. Michaelides

Since Specialization
Citations

This map shows the geographic impact of Michael R. Michaelides's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Michaelides with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Michaelides more than expected).

Fields of papers citing papers by Michael R. Michaelides

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Michaelides. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Michaelides. The network helps show where Michael R. Michaelides may publish in the future.

Co-authorship network of co-authors of Michael R. Michaelides

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Michaelides. A scholar is included among the top collaborators of Michael R. Michaelides based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Michaelides. Michael R. Michaelides is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Curtin, Michael L., Robin R. Frey, H. Robin Heyman, et al.. (2012). Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorganic & Medicinal Chemistry Letters. 22(9). 3208–3212. 19 indexed citations
2.
Curtin, Michael L., H. Robin Heyman, Robin R. Frey, et al.. (2012). Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. Bioorganic & Medicinal Chemistry Letters. 22(14). 4750–4755. 12 indexed citations
3.
Ji, Zhiqin, Yujia Dai, Cele Abad‐Zapatero, et al.. (2012). Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(14). 4528–4531. 5 indexed citations
4.
McClellan, William J., Yujia Dai, Cele Abad‐Zapatero, et al.. (2011). Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases. Bioorganic & Medicinal Chemistry Letters. 21(18). 5620–5624. 39 indexed citations
5.
Curtin, Michael L., Robin R. Frey, Niru B. Soni, et al.. (2011). Abstract C202: Discovery and initial characterization of the clinical compound ABT-348, a potent inhibitor of the VEGF, PDGF, and Aurora kinase families.. Molecular Cancer Therapeutics. 10(11_Supplement). C202–C202. 1 indexed citations
6.
Gracias, Vijaya, Zhiqin Ji, Irini Akritopoulou‐Zanze, et al.. (2008). Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(8). 2691–2695. 21 indexed citations
7.
Frey, Robin R., Michael L. Curtin, Daniel H. Albert, et al.. (2008). 7-Aminopyrazolo[1,5-a]pyrimidines as Potent Multitargeted Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry. 51(13). 3777–3787. 42 indexed citations
8.
Ji, Zhiqin, Asma A. Ahmed, Daniel H. Albert, et al.. (2008). 3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases. Journal of Medicinal Chemistry. 51(5). 1231–1241. 25 indexed citations
9.
Dai, Yujia, Niru B. Soni, Lori J. Pease, et al.. (2007). Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(1). 386–390. 31 indexed citations
10.
Dinges, Jürgen, Irini Akritopoulou‐Zanze, Lee D. Arnold, et al.. (2006). Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(16). 4371–4375. 19 indexed citations
11.
Heyman, H. Robin, Robin R. Frey, Peter F. Bousquet, et al.. (2006). Thienopyridine urea inhibitors of KDR kinase. Bioorganic & Medicinal Chemistry Letters. 17(5). 1246–1249. 33 indexed citations
12.
Dinges, Jürgen, Peter F. Bousquet, George A. Cunha, et al.. (2006). 1,4-Dihydroindeno[1,2-c]pyrazoles as novel multitargeted receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(16). 4266–4271. 15 indexed citations
13.
Guo, Jun, Patrick A. Marcotte, Jennifer McCall, et al.. (2006). Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Molecular Cancer Therapeutics. 5(4). 1007–1013. 53 indexed citations
14.
Li, Junling, Lori J. Pease, Paul Tapang, et al.. (2005). ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia. Cancer Research. 65. 1407–1407.
15.
Stavropoulos, Jason, Jonathan A. Meulbroek, Jacqueline M. O’Connor, et al.. (2005). Preclinical activity of ABT-869, a novel receptor tyrosine kinase inhibitor, alone or in combination with paclitaxel. Journal of Clinical Oncology. 23(16_suppl). 3175–3175. 4 indexed citations
16.
Curtin, Michael L., Robin R. Frey, H. Robin Heyman, et al.. (2004). Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(17). 4505–4509. 26 indexed citations
17.
18.
Michaelides, Michael R. & Michael L. Curtin. (1999). Recent Advances in Matrix Metalloproteinase Inhibitors Research. Current Pharmaceutical Design. 5(10). 787–819. 66 indexed citations
19.
Michaelides, Michael R., Robert Schoenleber, Sheela A. Thomas, et al.. (1991). Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. Journal of Medicinal Chemistry. 34(10). 2946–2953. 13 indexed citations
20.
Roush, William, et al.. (1989). A highly stereoselective synthesis of (+)-olivin, the aglycon of olivomycin A. Journal of the American Chemical Society. 111(8). 2984–2995. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stuart B. Rosenblum Breakdown of academic impact, for papers by Peter Chua Breakdown of academic impact, for papers by James M. Hamby Breakdown of academic impact, for papers by Kristi Leonard Breakdown of academic impact, for papers by H. Robin Heyman Breakdown of academic impact, for papers by Arthur G. Taveras Breakdown of academic impact, for papers by André Richters Breakdown of academic impact, for papers by Matthew Labenski Breakdown of academic impact, for papers by Sung Yun Cho Breakdown of academic impact, for papers by Robert A. Mantei
Rankless by CCL
2026